CLK1 and esophageal squamous cell carcinoma: In another study (21) involving 94 tumor and 24 nontumor tissue samples, 3 distinct ESCC subtypes (subtype I [S-I], S-II, and S-III) were identified, and the therapeutic potential of TG003, a CLK inhibitor, was confirmed specifically for patients with S-III.